CareDx, Inc

NASDAQ:CDNA

Medical - Diagnostics & Research

Healthcare
$74.44 +5.07%

+$1.19 today

Market cap
$3.91B
Beta
2.48
P/E (TTM)
-154.0
EPS (TTM)
-$0.16
52W Low $10.96High $24.96

Volume 0.54M

Average 0.74M

CDNA EBITDA Margin

EBITDA as a percentage of revenue.

CareDx, IncNASDAQ: CDNA

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 3.3%

EBITDA Margin was 3.3% in Q2 FY2026, up 9.9 pp from a year earlier. On a trailing-twelve-month basis it was 3.4%, up 11.1 pp year over year. Over 3 fiscal years it widened by 17.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 26.8% for the fiscal year ending Dec 2026, up from -1.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
3.3%-2.8 pp QoQ
Last fiscal yearDec 2025
-1.2%+9.0 pp YoY
LTMJun 2026
3.4%+11.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9.9 pp+15.5 pp+5.7 pp
1 year+9.0 pp+28.0 pp+19.0 pp
3 years+17.5 pp+26.0 pp+8.5 pp
5 years+33.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1.2%
Year-over-year change
+9.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CDNA compares with its peers on the latest reported figures

  • CDNA's LTM Jun 2026 EBITDA Margin of 3.4% is the 4th highest of the 8 companies compared; the peer median is -6.6%.
  • Its year-over-year change of +11.1 pp is the 3rd highest of 8, against a peer median of -1.6 pp.
  • Over three fiscal years its change of +17.5 pp compares with a peer median of +9.4 pp.
CDNA Competitors Peer median
EBITDA Margin for CDNA and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
VCYTVeracyte, Inc.LTM Jun 202623.1% +13.6 pp+20.8 pp
BLLNBillionToOne, Inc.LTM Jun 202612.6% +21.8 pp—
CDNACareDx, IncLTM Jun 20263.4% +11.1 pp+17.5 pp
NTRANatera, Inc.LTM Jun 2026-6.6% +4.2 pp+53.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-16.8% -24.5 pp+171.2 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-18.3% -9.7 pp-49.4 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
Peer median (excluding CDNA) -6.6%-1.6 pp+9.4 pp

Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue296.4M321.79M280.32M333.79M379.81M
Cost of Revenue97.39M112.21M102M109.63M123.24M
Gross Profit199.01M209.58M178.33M224.16M256.57M
Gross Margin67.1%65.1%63.6%67.2%67.6%
Research & Development76.53M90.39M81.87M72.41M71.43M
Selling, General & Admin152.21M196.42M201.2M205.5M210.21M
Operating Expenses228.73M286.81M381.69M183.39M281.64M
Depreciation & Amortization11.89M16.01M19.82M19.76M20.42M
EBITDA(20.2M)(60.23M)(84.92M)(34M)(4.66M)
EBITDA Margin-6.8%-18.7%-30.3%-10.2%-1.2%
Operating Income(29.73M)(77.23M)(203.36M)40.77M(25.07M)
Operating Margin-10.0%-24.0%-72.5%12.2%-6.6%
Interest Income160K3.76M11.87M11.77M9.17M
Interest Expense00000
Other Income / Expenses(2.36M)997K13.22M12.09M3.99M
Income Before Tax(32.09M)(76.23M)(190.14M)52.86M(21.08M)
Pre-Tax Margin-10.8%-23.7%-67.8%15.8%-5.6%
Income Tax Expense(1.43M)379K141K310K271K
Net Income(30.66M)(76.61M)(190.28M)52.55M(21.35M)
Net Margin-10.3%-23.8%-67.9%15.7%-5.6%
EPS (Basic)(0.59)(1.44)(3.54)1.00(0.40)
EPS (Diluted)(0.59)(1.44)(3.54)0.93(0.40)
Weighted Avg Shares52.24M53.32M53.76M52.77M53.29M
Weighted Avg Shares (Diluted)52.24M53.32M53.76M56.62M53.29M

CareDx, Inc

NASDAQ:CDNA

Intrinsic Alpha fair value

Locked

Current Price

$74.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.